Floatz logo

Tiragolumab

Epithelioid Sarcoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Epithelioid Sarcoma cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2BB
Nab-Rapamycin
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC
Nivolumab
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC
Atezolizumab
National Cancer Institute (NCI)
Phase 1/2CCC
Zoledronate
University of Florida
Phase 1/2CCC

View all 10 →

Same molecule, other indications

Tiragolumab is also rated in:

small cell lung carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
61 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →